source
- Verastem’s experimental KRAS drug shows early promise in small study, shares jump 18%Verastem Oncology announced early data from a small study of its experimental drug VS-7375, which targets the KRAS G12D mutation. The study enrolled patients with metastatic pancreatic ductal aden…
- Ultragenyx sells second priority review voucher as Biomea shares tumble after oral GLP-1 dataUltragenyx Pharmaceutical, a commercial-stage rare disease company, completed its second sale of a priority review voucher this month. The voucher sale reflects the company's strategy of monetizin…